|
Prothena Corporation plc (PRTA) DCF Valuation
IE | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Prothena Corporation plc (PRTA) Bundle
Enhance your investment choices with the Prothena Corporation plc (PRTA) DCF Calculator! Utilize real financial data from Prothena, adjust growth projections and expenses, and instantly observe how these changes affect the intrinsic value of Prothena Corporation plc (PRTA).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .8 | .9 | 200.6 | 53.9 | 91.4 | 114.5 | 143.4 | 179.7 | 225.2 | 282.1 |
| Revenue Growth, % | 0 | 4.79 | 23414.3 | -73.13 | 69.5 | 25.29 | 25.29 | 25.29 | 25.29 | 25.29 |
| EBITDA | -78.9 | -111.2 | 72.0 | -131.6 | -190.1 | -83.4 | -104.5 | -130.9 | -164.0 | -205.4 |
| EBITDA, % | -9697.54 | -13038.69 | 35.88 | -244.05 | -208.06 | -72.82 | -72.82 | -72.82 | -72.82 | -72.82 |
| Depreciation | 6.8 | 7.0 | 6.8 | 6.7 | .9 | 49.7 | 62.2 | 78.0 | 97.7 | 122.4 |
| Depreciation, % | 837.84 | 817.94 | 3.39 | 12.51 | 1.02 | 43.38 | 43.38 | 43.38 | 43.38 | 43.38 |
| EBIT | -85.8 | -118.2 | 65.2 | -138.3 | -191.0 | -84.1 | -105.4 | -132.1 | -165.5 | -207.4 |
| EBIT, % | -10535.38 | -13856.62 | 32.49 | -256.56 | -209.08 | -73.5 | -73.5 | -73.5 | -73.5 | -73.5 |
| Total Cash | 375.7 | 295.4 | 579.1 | 710.4 | 618.8 | 114.5 | 143.4 | 179.7 | 225.2 | 282.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .0 | .0 | .1 | 5.2 | 3.6 | 4.6 | 5.7 | 7.2 | 9.0 |
| Account Receivables, % | 8.35 | 1.76 | 0.0064813 | 0.11502 | 5.65 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
| Inventories | -.1 | 1.4 | .0 | -.1 | .0 | 21.0 | 26.3 | 32.9 | 41.2 | 51.6 |
| Inventories, % | -8.35 | 158.5 | -0.0064813 | -0.11502 | 0 | 18.3 | 18.3 | 18.3 | 18.3 | 18.3 |
| Accounts Payable | 1.2 | 4.1 | 3.7 | 9.3 | 25.4 | 56.5 | 70.8 | 88.7 | 111.2 | 139.3 |
| Accounts Payable, % | 152.58 | 482.65 | 1.84 | 17.2 | 27.79 | 49.37 | 49.37 | 49.37 | 49.37 | 49.37 |
| Capital Expenditure | -.6 | -.2 | -.6 | -.5 | -2.8 | -21.8 | -27.4 | -34.3 | -43.0 | -53.8 |
| Capital Expenditure, % | -68.18 | -22.98 | -0.28667 | -0.86077 | -3.08 | -19.08 | -19.08 | -19.08 | -19.08 | -19.08 |
| Tax Rate, % | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 | 8.38 |
| EBITAT | -86.2 | -117.9 | 60.7 | -128.8 | -175.0 | -80.4 | -100.7 | -126.2 | -158.1 | -198.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -78.7 | -109.6 | 67.9 | -116.9 | -165.9 | -40.9 | -57.8 | -72.4 | -90.7 | -113.6 |
| WACC, % | 5.38 | 5.38 | 5.38 | 5.38 | 5.37 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -313.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -116 | |||||||||
| Terminal Value | -3,431 | |||||||||
| Present Terminal Value | -2,641 | |||||||||
| Enterprise Value | -2,954 | |||||||||
| Net Debt | -607 | |||||||||
| Equity Value | -2,347 | |||||||||
| Diluted Shares Outstanding, MM | 53 | |||||||||
| Equity Value Per Share | -44.11 |
What You Will Receive
- Comprehensive Financial Model: Prothena Corporation plc’s actual data provides an accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates allow you to see results instantly as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue projections, operating margin, and research & development expenses.
- Instant DCF Valuation: Automatically computes intrinsic value, net present value, and other key financial metrics.
- High-Precision Estimates: Incorporates Prothena’s actual financial data for accurate valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and analyze results with ease.
- Efficiency Booster: Streamline the valuation process without the hassle of creating intricate models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Prothena Corporation plc’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update instantly as you adjust your assumptions.
- Step 5: Analyze the outputs and leverage the results for your investment decisions.
Why Choose Prothena Corporation plc (PRTA)?
- Innovative Solutions: Pioneering advancements in neuroscience and protein misfolding.
- Strong Pipeline: Diverse portfolio of therapies targeting significant unmet medical needs.
- Expert Team: Led by experienced professionals dedicated to scientific excellence.
- Commitment to Quality: Adherence to rigorous standards in research and development.
- Proven Track Record: Established history of successful collaborations and partnerships.
Who Should Use This Product?
- Investors: Gain insights and make informed decisions with Prothena's innovative solutions.
- Healthcare Analysts: Streamline your research with comprehensive data on Prothena's pipeline and market potential.
- Consultants: Efficiently tailor presentations or reports focusing on Prothena's advancements in biotechnology.
- Biotech Enthusiasts: Enhance your knowledge of drug development processes and industry trends through Prothena's resources.
- Educators and Students: Utilize Prothena's materials as a practical reference in biotechnology and pharmaceutical studies.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Prothena Corporation plc (PRTA) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Prothena Corporation plc (PRTA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.